CD33 monoclonal antibodies recognize a 67-kD glycoprotein of unknown function that is expressed by early myeloid progenitors and their leukemic counterparts. We report here the cloning of the murine homolog of the human CD33 antigen. Two cDNA clones, differing by an 83-nucleotide insertion in the cytoplasmic region, were isolated. The insertion generated a shift in the reading frame within the cytoplasmic tail, resulting in two mouse CD33 isoforms, m33-A and m33-B, with distinct cytoplasmic domains and with predicted protein core molecular weights of 37 kD and 45 kD, respectively. The cDNAs and deduced amino acid sequences show extensive similarity with the human CD33 sequence with the high-N THE HUMAN hematopoietic system, CD33 monoclonal antibodies (MoAbs) recognize, under reducing conditions, a 67-kD cell surface glycoprotein. The expression of this molecule is largely restricted to the monocytic/ myeloid lineage.' CD33 antigen is detected on multipotential colony-forming cells, progenitors of granulocytes and macrophages, early erythroid progenitors, and mast cell^.^^^ In addition, the antigen is found on myelocytes, a proportion of metamyelocytes, and monocytes. It is expressed only weakly by terminally differentiated granulocytes and not at all by normal lymphoid cells.
alter the level of CD33 mRNA transcripts or protein expression.'.6 Despite the similarity of CD33 to other adhesion molecules, the function of the CD33 antigen is still unknown.
To help elucidate its function we have cloned the murine CD33 homolog and have analyzed its expression in various hematopoietic and nonhematopoietic tissues and cell lines using Northern analysis and the reverse transcriptase polymerase chain reaction (RT-PCR). We report here the isolation of two cDNA clones, that represent the products of alternatively spliced mRNAs. These appear to encode two murine CD33 isoforms with distinct cytoplasmic domains.
MATERIALS AND METHODS

Cell lines and tissues. The human lymphomyeloid cell line KG1 '
was maintained in Iscove's modified Dulbecco's medium supplemented with 10% fetal calf serum. Human peripheral blood mononuclear cells (PBMCs) were isolated from blood freshly drawn from consenting adults by centifugation over Ficoll-Hypaque (Pharmacia, Uppsala, Switzerland) (density < 1.077 g/mL).
The murine cell lines used were: the multipotential hematopoietic progenitor cell line A4 (FDCP mix), a gift from Dr Elaine Spooncer, Paterson Institute, Manchester'; the B-cell lines NS-I myeloma' and A20 lymphoma"; the myelomonocytic cell line WEHI 3B" and myeloid cell line MI"; T-cell lines EL-4" and RMAI4; the monocyte-macrophage cell line P388"; the mastocytoma cell line and the breast carcinoma cell line 410.4.'7 These were cultured as de~cribed."~'~ Liver, thymus, spleen, kidney, brain, and bone marrow (BM) were isolated from 6-to 8-week-old BALB/c mice.
RT-PCR. A cDNA fragment of human CD33 was generated from the KG1 cell line by RT-PCR using primers corresponding to hCD33 nucleotide 254-274 and 61 1-593. All primers sequences are shown in Table 1 . Total RNA was isolated from KG1 cells by the guanidinium isothiocyanate method.'* Two micrograms of total RNA was reverse transcribed in 20 pL of buffer comprising SO mmol/L TRIS-HCI pH 8. The numbering of the murine CD33 primers refers to the m33-B isoform.
primer. After initial denaturation at 94°C for IO minutes, 1 U Taq polymerase (Promega) was added and PCR amplification was performed for 30 cycles. Each cycle consisted of denaturing at 94°C for 1 minute, annealing at 57°C for 1 minute and elongation at 72°C for 2 minutes. After the last cycle, the sample was maintained at 72°C for 10 minutes. The 358-bp PCR amplified product was cloned into pT7 BlueTVector (AMs Biotechnology; Oxon, UK) and its identity to the appropriate human CD33 sequence confirmed by sequencing. The 358-bp hCD33 fragment was labeled by random priming" in the presence of a-"PdCTP (Amersham International, Aylesbury, UK) to a specific activity of greater than 1 X 10' dpndpg, purified by chromatography through a Nick Column (Pharmacia) and used as a probe in Southern blotting and to screen a BALB/c mouse bone marrow cDNA library.
Southern blot analysis. Genomic DNA was isolated from human peripheral blood mononuclear cells (PBMCs) and BALBk mouse spleen cells, according to standard methods." A total of 10 pg of DNA was digested with Pst I, fractionated in 0.9% (wt/vol) agarose gel and transferred to Hybond N membrane (Amersham International). The blot was hybridized to the 358-bp PCR-amplified fragment of human CD33 cDNA described above in 5X saline sodium citrate (SSC: 150 rnmovL NaC1, 15 mm01 trisodium citrate), 5X Denhardt's solution, 0.5% (wt/vol) sodium dodecyl sulfate (SDS) and 100 pg/mL denatured salmon sperm DNA at 65°C. The blot was washed at 65°C in 0.1x SSC and 0.1% (wt/vol) SDS.
cDNA library screening. A BALBIc mouse BM cDNA library in Agtll (Clontech, Palo Alto, CA) was screened using as a probe the PCR-amplified fragment of the human CD33 cDNA (see above). Lifts were performed using nitrocellulose filters (Schleicher and Schuell, Keene, NH). Hybridization was performed in 5 x SSC, 5 x Denhardt's solution, 0.5% (wt/vol) SDS and 100 pg/mL sonicated denatured salmon sperm DNA at 65°C. The filters were washed at 65°C with I X SSC, containing 0.1% (wt/vol) SDS.
Of the 150,000 plaques screened, 11 positive clones were isolated. These clones contained two types of inserts, eight had an insert of 1,330 bp and three of 1,213 bp, as judged by sequencing and PCR analysis. Double-stranded DNA was sequenced by the dideoxy termination method" using the Sequenase 2.0 kit (US Biochemical, Cleveland, OH). Both strands of each insert were sequenced entirely using specific oligonucleotide primers. PCR analysis was performed, as described above, using Agtl 1 specific primers, flanking the EcoRI cloning site of the Agtl 1 phage (Table 1) .
Inserts were isolated from A vectors and subcloned into pBluescript SK (Stratagene, La Jolla, CA) using standard procedures." These clones will be referred to as p33-A (for the 1.330-bp clone) and p33-B (for the 1,213-bp clone). Both were missing 5' sequences of mouse CD33 and these were determined by the 5' rapid-amplification-of-cDNA-ends (RACE) system, as described below.
SRACE. The 5'RACE System (GIBCO-BRL) was used to isolate the 5' end of the mouse CD33 cDNA according to the manufacturers's instructions. Total RNA was extracted from BALBk mouse BM, as described above, and the first strand cDNA synthesis was performed, using M1 anti-sense mouse CD33 primer, corresponding to nucleotides 1,093-1,074 ( Table 1 ). The cDNA was purified, poly(C) tailed, and amplified by PCR using a 5'RACE Universal Amplification Primer (GIBCO-BRL) and M2 antisense mouse CD33 primer (600-580). The PCR products were size fractionated, purified, subcloned into p l 7 BlueT-Vector (AMs Biotechnology), and sequenced. This clone will be referred to as p33-RACE.
The RACE-derived 5' sequence was confirmed by sequencing three additional independent PCR clones, generated from the 5'-end region. These PCR clones were amplified from mouse BM RNA, using an M3 sense primer identical to nucleotides 2-22 and M2 antisense primer.
Northern blot analysis. Total RNA (20 pg) was separated in 1% (voVvol) formaldehyde gel and transferred to Gene Screen plus membrane filters (New England Nuclear Research Products, Boston, MA). The blot was hybridized to the p33-B clone at 42°C in 50% (voVvol) formamide, 1% (wt/vol) SDS, 1 m o m NaCI, 10% (wt/vol) dextran sulphate, 100 pg/mL denatured salmon sperm DNA and washed at 60°C in 0.2X SSC, 0.1% (wt/vol) SDS. The blot was stripped and rehybridized to a 1.8 kb mouse &actin probe, kindly provided by Dr Alastair Reith (Ludwig Institute for Cancer Research, London Middlesex Branch, UK).
Analysis of splice variants. Primers MI, M4, and M5 (Table l) , encompassing the spliced region, were designed for detection of the alternatively spliced variants. As a PCR control, a 428-bp murine &actin fragment was amplified with primers shown in Table 1 . PCR conditions were as described above. To detect possible genomic DNA contamination for each sample, a respective control without reverse transcriptase was amplified as well.
Computer analyses. Computer analyses of DNA and amino acid sequences were performed on a DAP 610 computer using Bio Search software (University of Edinburgh, UK) developed by J.F. Collins and A.F.W. Coulson." For assessing amino acid homologies, the program searches the compiled Swiss-Prot (Geneva, Switzerland), PIR (Geneva, Switzerland), Brookhaven (Upton, NY), and GEN-BANK (Washington) databases (containing 58,701 entries), and for nucleic acid sequences, the EMBL database (Heidelberg, Germany). The ALIGN program (Intelligenetics, Mountain View, CA) was also used for direct comparison of the sequences.
RESULTS
Isolation and analysis of murine CD33 cDNAs. A Souihem blot of mouse genomic DNA was probed with a PCRamplified cDNA fragment, corresponding to most of the second Ig domain of human CD33 (data not shown). The probe cross-hybridized under high stringency indicating some degree of conservation of the gene. This PCR product was subsequently used to screen a cDNA library derived from mouse BM, where CD33 is known to be highly expressed in the human. Two independent cDNA clones, p33-A and p33-B, were isolated and analyzed. The close homology of their sequences to human CD33 indicates that they represent 
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** * * ** *.* * * ** * ***.****. * * X " . . * * the murine homolog for human CD33. Both cDNA clones RACE clone contained an additional 348 nucleotides 5' of covered a total of 1,614 bp, stretching from the 3' untransthe clone p33-B. To confirm the 5' RACE-derived sequence, lated region to a position, corresponding to 354 bp from the three additional independent PCR clones covering the 5'-5' end of the human CD33 cDNA sequence. The 5' end of end region were generated. They were amplified from mouse the cDNA was isolated using the 5'RACE system. The p33-BM RNA, using primers deduced from the p33-RACE se- The compiled PIR, Swiss-Prot, Brookhaven, and GENBANK databases were searched for similarities to the murine CD33-A protein sequence using Bio Search Software. The alignment scores represent the highest score between alignment of mCD33-A and those within the data banks within one search.
quence. The sequences from the PCR-derived clones matched those of p33-RACE. Predicted amino acid sequence. The deduced protein sequence of the mouse CD33 has the typical features of a transmembrane protein, with an extracellular domain of 240 residues, hydrophobic transmembrane domain of 27 residues and a cytoplasmic tail of variable length (Fig 1) . The 83-bp insertion in m33-B results in a shift of the reading frame generating a new cytoplasmic portion (after residue 286). The predicted mature forms of m33-A and m33-B consist of 334 and 403 residues, with cytoplasmic tails of 67 and 136 amino acids, respectively.
The sequence begins with a putative hydrophobic signal peptide that is likely to be cleaved between Ala-l6 and Gln-17, according to the predictive method of von Heijne.24 The extracellular domain consist of two Ig-like domains between residues 18-130 and 152-232. The amino terminal Ig-like domain is of the V-SET family, whereas the second Ig-like domain is of the C2-SET type.25 This region contains three potential N-glycosylation sites (Asn-X-Ser/Thr) and a possible glycosaminoglycan attachment site (SerGlyAlaGly) at residue 217. The predicted mass for the polypeptide backbone of 37 kD and 45 kD for m33-A and m33-B. respectively, is expected to differ significantly from that observed because of the presence of carbohydrates and the probable presence of glycans.
Multiple putative phosphorylation targets are found in the cytoplasmic domains of m33-A and m33-B. The identical overlapping intracellular portion of both isoforms contains two 3'4' adenosine monophosphate (CAMP)-and 3'-5' guanosine monophosphate (GMP)-dependent protein kinase phosphorylation sites at positions 269 and 2702' and one protein kinase C serinekhreonine phosphorylation site (PKC) is present at residue 272 (Fig lA) ." The cytoplasmic region of m33-A has two sequences corresponding to casein kinase 2 (CK 2) phosphorylation sites at positions 296 and 308.'' In m33-B, the 83-bp insertion, leading to the frame shift, introduces four additional PKC consensus recognition sequences at residues 319, 344, 355, and 359 ( Fig IA) and changes the CK 2 sites to one site at position 301. There is one tyrosine residue in the cytoplasmic domain of m33-A (position 331) and there are two in m33-B (positions 294 and 332), not lying in "YLYL" motifs, that are known to be associated with signal transduction."
Homology to human CD33 and other proteins. The cDNAs and their derived amino acid sequences described above are highly homologous to human CD33. The similarity is highest at the 5' end in the extracellular Ig domains, where 66% of the nucleotides and 61% of the amino acids are identical. Figure 2A depicts the alignment between the two amino acid sequences. As expected for Ig-like proteins, all of the extracellular cysteine residues are conserved between the murine and human proteins. The N-linked glycosylation sites are also maintained, whereas the possible GAG attachment site in the murine sequence is not present in human CD33. Alignment of the transmembrane regions shows a 55% amino acid identity. Although at a much lower level (27% amino acid identity), the homology with the human sequence extends within the cytoplasmic region of the shorter murine m33-A isoform. However, significant divergence occurs between the 3' cytoplasmic domain of human CD33 and the murine m33-B isoform. The overall amino acid identity between the human and murine m33-A isoform is 53% and considering the conservative replacements the similarity reaches 71 %.
A database search using Bio Search software shows extensive similarity to the MAG, as previously described for hCD33.6 A very good alignment (24% identity, 53% similarity over 2.59 amino acids) was observed between the first and second Ig domains of mCD33 and MAG (Table 2) , although the RGD (Arg-Gly-Asp) cell attachment site in MAG is not present in the murine CD33 sequence. A segment of limited similarity in the cytoplasmic domain has been detected by direct alignment between the cytoplasmic domain of m33-B and the cytoplasmic domain of the longer form of murine MAG (MAG-L) (Fig 2B) .
In its amino terminal region murine CD33 is also homologous to other members of the Ig gene superfamily such as CD22, murine biliary glycoprotein (BGP), and the T-cell surface glycoprotein, CD4 ( Table 2) . As with mCD33, all contain the typical pattern of an amino terminal V-SET Ig domain followed by a variable number of C2-SET Ig-like domains with an additional V-like domain in CD4.
The inserted segment of 83 bp in m33-B and its derived amino acid sequence do not show statistically significant homologies to any other sequence in the database.
Expression of murine CD33. The p33-B cDNA clone, was used to analyze the expression, at the RNA level, of the murine gene in various hematopoietic and nonhematopoietic tissues and cell lines. Northern blot analysis (Fig 3) shows two mRNA species of approximately 3.9 kb and 2.0 kb. Under the conditions used, both sizes of transcript are observed in BM only, with higher levels of the larger (3.9 kb) mRNA. The 3.9-kb transcript is expressed highly in the thymus and the macrophage cell line P388. After a longer exposure a very faint 3.9-kb band is found in the brain and liver, perhaps because of the presence of microglia and Kupffer cells, respectively (data not shown). The smaller 2.0-kb mRNA, in addition to being present in the BM, is observed at a lower level in the spleen, the myeloid cell line MI, the myelomonocytic cell line WEHI 3B, and in the multipotential progenitor cell line A4. A band of 4.4 kb appears in all cell lines and is probably an artefact caused by nonspecific binding to the 28s ribosomal RNA (Fig 3B) . When the filter was washed under low stringency conditions, this band was also present in the murine tissues. A minor 6-kb RNA species was evident in WEHI 3B, A4, and M1 cells (arrow in Fig  3B) . This may represent an incompletely spliced mRNA. CD33 message could not be detected by Northern blot analysis in the cell lines EL4 and RMA (T cell), NS-1, and A20 (B cell), 410.4 (breast carcinoma cell line), and P815 (mastocytoma cell line). Two sizes of RNA transcripts (of 1.5 kb and 1.8 kb) have also been observed for the human CD33. 6 The two murine CD33 transcripts may arise from the use of alternative polyadenylation signals.
Analysis of splice variants. The sites of the 83-bp insertion in m33-B cDNA are flanked by consensus splice exon donor-acceptor sites. The 5' ends of exons are usually G or A and the 3' ends of exons CIAAG." This suggests alternative splicing between two exons (Fig 4A) . The 83-bp inserted fragment begins with A and ends with CAG, whereas the first nucleotide after the insertion (the beginning of the next putative exon, position 950) is G. The last three nucleotides of the previous exon, positions 863 through 865 are AAG.
To clarify whether the 83-bp insertion in m33-B is a cloning artefact or represents a differentially spliced variant, we looked for the presence of this region by RT-PCR. Primers, allowing the specific detection of both spliced variants were designed. These are shown schematically in Fig 4A. M4 and M1 are primers adjacent to the site of the insertion and so would give two bands differing by 83 bp, ie, products of 344 bp for m33-A isoform and of 427 bp for m33-B. Bands of both expected sizes, corresponding to the two isoforms, are amplified in BM, spleen, thymus, liver, brain, the multipotential progenitor cell line, A4, the myelomonocytic cell line, WEHI3B, and the myeloid cell line, M1 (Fig 4B) . The m33-A product is the most abundant form, suggesting that m33-B may be a minor transcript. Only one PCR product corresponding to the m33-A isoform is detected in macrophage cell line P388. No m33-A or m33-B transcripts were detected in EL-4, A-20, and the remaining cell lines that were also negative in Northern blot analysis (Fig 3B and  4B) . The absence of m33-B isoform in the P388 cell line is also confirmed by amplification with primers M4 and M5 (Fig 4C) , M5 being an internal primer from the inserted segment (Fig 4A) . This pair of primers was designed to generate a band of 265 bp only if m33-B is expressed and such a band is detected in all the expected RT-PCR positive samples shown in Fig 4B, ie, bone marrow, spleen, thymus , liver, brain, and the cell lines, WEHI 3B, A4, and M1 ( Fig  4C) . The presence of RNA in the samples tested was confirmed using @actin oligonucleotide primers in RT-PCR analysis (Fig 4D) . The PCR analyses were performed with and without reverse transcription to detect any genomic contamination. No definitive signals were found when reverse transcriptase was omitted (data not shown).
The RT-PCR results, together with the consensus 3'15' splice exon boundaries suggest that the two cDNAs clones represent the products of alternative splicing. The pattern of expression of the splice variants obtained by RT-PCR does not correlate with the Northern blot distribution of the two size transcripts of 3.9 kb and 2.0 kb. This suggest that both murine isoforms, m33-A and m33-B, could be derived from either of the two mFWAs species, of 2.0 kb and 3.9 kb, observed in Northem blot analysis. A detailed study of the gene structure and, ultimately, analysis of the proteins should resolve this question.
DISCUSSION
In this study, we describe the molecular cloning of the murine homolog of the human myeloid CD33 antigen. Two cDNA clones were isolated, which differed by an 83-bp insertion in the cytoplasmic portion. The inserted segment yielded a new translation reading frame, resulting in two mouse CD33 isoforms, m33-A and m33-B, with different cytoplasmic domains and apparent polypeptide core molecular weights of 37 kD and 45 k D , respectively. The cDNAs and derived amino acid sequences reported here share the general structural characteristics of members of the Ig gene superfamily and show extensive similarity to human CD33 (71% overall amino acid similarity). The regions with the most significant similarities between the human and mouse species include the first and second Ig-like domains. This suggests that these regions are important for CD33 function. Less conserved are the cytoplasmic domains, with the most significant divergence in their C-termini occurring, between human CD33 and the murine m33-B isoform.
In its extracellular portion mCD33 shows 53% homology with MAG, a cell surface molecule expressed by oligodendrocytes and Schwann cells.3' MAG has been shown to mediate cell-cell adhesion (neuron-oligodendrocyte and oligodendrocyte-oligodendrocyte)3*~33 as well cell-extracellular matrix interactions with heparin and different collagen types.34 In its amino terminal region, murine CD33 is also homologous to other cell adhesion molecules such as CD22, the carcinoembryonic antigen (CEA) family member, BGP, Total RNA (20 pg) extracted from the indicated tissues (A) and cell lines (B) was electrophoresed in formaldehyde agarose gel, transfered to nylon and hybridized with '*P-labeled p33-B cDNA probe or mouse p-actin.
- 2'4 The arrow indicates a band that is probably an incompletely spliced mRNA. here is splicing that results in out-of-frame translation. Such splicing has been observed for BGP'X." and CGMIY splice variants, resulting in a frame shift and generating unique cytoplasmic regions. The biologic significance of the different cytoplasmic domains of murine CD33 isoforms needs to be resolved. In this respect, it is interesting that the alternative splicing of murine CD33 mRNAs generates distinct potential phosphorylation sites in the cytoplasmic tails of the two variants. Five PKC consensus sequences were found in m33-B. compared with one PKC site in m33-A and in human CD33. Casein kinase 2 and CAMP-and cGMP-dependent protein kinase phosphorylation sites are also predicted. The phosphorylation of human CD33 has not been studied. However, the cytoplasmic portions of the m33-R variant share limited similarity to L-MAG. Although the function of the distinct cyto-plasmic domains of MAG isoforms are not yet clear, their developmentally regulated expression suggests an important role of L-MAG in myelin f~r m a t i o n .~~ Both MAG isoforms have been shown to be phosphorylated in a heterologous cell Furthermore L-MAG has been proposed to be the likely substrate in vivo for pp60v-src tyrosine kinase a~tivity,~' whereas the intracellular domain of the rat BGP isoform (C-CAM-l), which is also phosphorylated" is thought to act as a substrate for the insulin receptor tyrosine kinase."' As with the integrins where the phosphorylation is commonly involved in the regulation of affinity for their it is possible that the adhesive properties of molecules, such as MAG and BGP, and possibly of CD33, are also modulated by the differential splicing in their cytoplasmic domains. The splice variants might also serve to transduce different signals from the extracellular ligands to the cell interior. Certainly it has been shown that MAG transduces cell surface events to intracellular signals by modulating the activity of protein tyrosine kinases or phosphatases, with resulting inhibition of tubulin phosphorylation."
Although antibodies to murine CD33 would provide more accurate information of CD33 expression at the protein level, the similarity between the murine and human CD33 molecules is paralleled by their mRNA expression pattern. Northern blot analysis showed expression of murine CD33 in BM, spleen, thymus, liver, brain, the multipotential progenitor cell line A4, the myelomonocytic cell line WEHI 3B, the myeloid cell line M1, and the macrophage cell line P388.
These observations were supported and extended by preliminary in situ hybridization analysis. The in situ hybridization of p33-B clone in brain and spleen is confined to the microglia and red pulp, respectively. Strong expression was observed in the subcapsular regions of lymph nodes. Thus, murine CD33 mRNAs were detected in those regions, in which macrophages can be shown by immunocytochemistry.52 At first sight, it was unexpected to obtain a strong CD33 signal in Northern analysis of mouse thymus; however, staining of human thymus sections with CD33 MoAbs shows CD33+ macrophages and dendritic cells (our unpublished data). The preliminary in situ hybridization of BM cells suggests that the most prominent expression is on early myeloid cells, but not in lymphoid, erythroid, granulocytic, or megakaryocytic lineages in significant amounts. More detailed in situ analysis is needed to determine the precise localization of murine CD33 mRNAs in different tissues and its association with various subpopulations of macrophages. Together these data indicate that CD33 expression in the mouse, like that in humans, is confined to the hematopoietic system and largely limited to the myelomonocytic lineage. This suggests that the function of CD33 in hematopoiesis may be conserved between humans and mice.
The two murine CD33 mRNA species identified by Northem analysis appear to be differentially expressed in the adult tissues of mice. The larger (3.9-kb) size transcript is expressed abundantly in BM and thymus and is found at low levels in liver and brain, but not in spleen. On the other hand, the 2.0-kb mRNA is expressed in BM and spleen only. The restricted expression of the 3.9-kb transcript to the mature macrophage cell line P388, and of the 2.0-kb transcript to the multipotential progenitor cell line A4, nlyelomonocytic cell line WEHI 3B, and myeloid precursor cell line M1 suggests that differential polyadenylation of one or both CD33 isoforms may occur in myeloid precursors and in mature macrophage subpopulations. Furthermore, the RT-PCR analyses indicate that the mCD33-B isoform occurs in the myeloid precursors, but not in a subset of mature macrophages. The presence of two mRNA species could also confer heterogeneity in mRNA stability. There is only one ATTTA motif at position I ,27 1 in the 3'UTR. Similar motifs are commonly found in the 3'UTR of lymphokines and proto-oncogenes and are also thought to be mRNA instability Thus, the existence of two transcripts, each able to encode either of the splice variants, might suggest that these molecules are specifically expressed at different stages of myeloid maturation, in different tissues or during neoplastic development.
The function of CD33 is unknown. Based on the observed similarities, CD33 may function as an adhesion molecule. The presence of glycosaminoglycan attachment site in the second Ig-like domain suggests that the mouse CD33 antigen may have a role in cell-cell or cell-matrix interactions or that it may act to bind growth factors. The availability of murine CD33 cDNAs will undoubtedly help in determining the function of CD33 antigen and its distinctive cytoplasmic domains.
